

Health Advances LLC
275 Grove St.
Suite 1-300
Newton, MA 02466
USA

The Board of Directors
Oxford Nanopore Technologies plc
Gosling Building
Edmund Halley Road
Oxford Science Park
Oxford
OX4 4DQ

2021

Dear Sir/Madam,

30 September

Oxford Nanopore Technologies plc (the “Company”) – Prospectus Consent Letter

We refer to our report entitled “Application Market Sizing – Short Summary report”, presented to the Company on 10 March 2021 and summarized in August 2021 (the “**Report**”).

We consent to the inclusion in the prospectus of the Company dated 30 September 2021 (the “**Prospectus**”) of our name, Health Advances LLC, and the information sourced from the Report, in the form and context in which it appears for the purposes of item 1.3 of Annex 1 of Commission Delegated Regulation (EU) 2019/980 as it forms part of retained EU law as defined in the EU (Withdrawal) Act 2018 (the “**UK Commission Delegated Regulation**”), and to the Report being put on public display in accordance with item 21.1 of Annex 1 of the UK Commission Delegated Regulation.

We authorize, and as required by item 1.2 of Annex 1 of the UK Commission Delegated Regulation and for the purposes of Rule 5.3.2R(2)(f) of the FCA Prospectus Regulation Rules, accordingly take responsibility for those statements in the Prospectus which are specifically attributed to us and confirm that, to the best of our knowledge, the information contained in the Prospectus sourced from the Report is in accordance with the facts and makes no omission likely to affect its import.

Yours faithfully,



Name: Tracy Walters

For and on behalf of Health Advances LLC